The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Exploring Novel Agents to Target Pathways in Lymphoma

Julie M. Vose, MD, MBA
Published Online:4:49 PM, Thu August 9, 2018


Julie M. Vose, MD, MBA, Chief in the Division of Oncology/Hematology at the University of Nebraska Medical Center, discusses strategies for overcoming resistance in lymphoma during the 2018 Pan Pacific Lymphoma Conference. 

While many patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, are able to be cured, there are still many patients that cannot be cured, and the reason is still unclear, Vose explains. 

It is important to look at the specific genetic makeup of the patient's lymphoma and use drugs that can target certain pathways that appear to be abnormal in the cell. However, a patient can have multiple pathways that are abnormal. Physicians still need to understand the best way to use agents, likely in combination, to overcome that escape mechanism, she says.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.